Clinical trials: Systemic Embolism
Atrial Fibrillation
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
- Trial name
- NCT00494871
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- 165 sites in Japan
- Volunteers
- 1,280 people
- Sponsor
- Bayer
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
- Trial name
- NCT00378521
- Testing
- MQX-503
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Raynaud's Phenomenon, Systemic Sclerosis
The Effect of Physical Therapy on Raynaud's Phenomenon Secondary to Systemic Sclerosis
The effect of deep oscillation and biofeedback on Raynaud's phenomenon secondary to systemic sclerosis (SSc) remains to be determined.
- Trial name
- NCT00946738
- Testing
- Biofeedback, Deep oscillation
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Charite University, Berlin, Germany
Raynaud Phenomenon Due to Trauma, Raynaud Disease
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Objective: To compare the efficacy of topical 10% nifedipine versus 5% sildenafil in patients with secondary Raynaud's phenomenon (RP).
- Conditions
- Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic
- Trial name
- NCT03027674
- Testing
- 10% nifedipine cream, 5% sildenafil cream
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Systemic Sclerosis
CSL Behring Sclero XIII
Many patients with Scleroderma (Systemic sclerosis) experience damage to blood vessels, mainly to the small arteries. A common manifestation of this is Raynaud's phenomenon (fingers or toes turning white then blue in the cold)…
- Trial name
- NCT02551042
- Testing
- Fibrogammin®P, coagulation factor XIII concentrate (Human), 0.9% sodium chloride
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College, London
Arrhythmia, Acute Kidney Injuries
This is an Observational Study That Aims to Demonstrate Postoperative Risk Factors in Pediatric Cardiac Surgery
This retrospective observational study aims to identify risk factors for postoperative complications in children undergoing cardiac surgery at a tertiary hospital in Brazil.
- Conditions
- Arrhythmia, Acute Kidney Injuries, Sepsis, Pneumopathy
- Trial name
- PEDS-CARE (NCT06985082)
- Testing
- THERE IS NOT A INTERVENTION
- Volunteers
- 310 people
- Sponsor
- Instituto de Cardiologia do Rio Grande do Sul
Cardiogenic Shock, Malignant Arrhythmias
The Caribbean Registry of Extracorporeal Membrane Oxygenation (ECMO) From the University Hospital in Martinique
The project's main goal is to collect baseline clinical and procedural data as well as to assess clinical outcomes for all patients undergoing VV, VA or VAV ECMO implantation in the French West Indies and Guiana.
- Conditions
- Cardiogenic Shock, Malignant Arrhythmias, Ischemic or Valvular Heart Failure, Drepanocytosis and Thoracic Syndrome
- Trial name
- NCT07351435
- Volunteers
- 1,200 people
- Sponsor
- University of Genova
Liver Cirrhosis, Portal Hypertension
Freiburg TIPS Registry
Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will…
- Conditions
- Liver Cirrhosis, Portal Hypertension, Non-Cirrhotic Portal Hypertension, Budd Chiari Syndrome
- Trial name
- FRETIR (NCT05782556)
- Testing
- Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- University Hospital Freiburg
Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke
Researchers are looking for a better way to treat people with atrial fibrillation (AF) and prevent stroke or systemic embolism (blood clots travelling through the blood stream to plug another vessel).
- Trial name
- OCEANIC-AF (NCT05643573)
- Testing
- Asundexian (BAY2433334), Apixaban
- Where
- 1,069 sites in United States, Argentina and 36 more
- Volunteers
- 14,830 people
- Sponsor
- Bayer
CREST Syndrome, Calcinosis Cutis
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
Background CREST is an acronym for the cardinal clinical features of the syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) and part of the heterogeneous group of sclerodermas.
- Conditions
- CREST Syndrome, Calcinosis Cutis, Raynaud Phenomenon
- Trial name
- NCT03972566
- Testing
- INOMAX
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- RoseLab Skin Optics Laboratory
Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and Surveillance
PERSEUS is an academic, investigator-initiated, multicenter observational registry of adults with acute pulmonary embolism (PE), promoted by Azienda Ospedaliero-Universitaria Careggi (Florence, Italy).
- Conditions
- Venous Thromboembolism (VTE), Chronic Thromboembolic Pulmonary Hypertension, Right Ventricular Dysfunction, Pulmonary Embolism (PE)
- Trial name
- PERSEUS (NCT07855679)
- Testing
- Routine clinical care (no study intervention)
- Where
- 16 sites in Italy, Poland and 1 more
- Volunteers
- 5,000 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Systemic Sclerosis
Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction
Purpose of the study is to evaluate the effectiveness and safety of a new investigational dur, IC351. Study is designed to gather information regarding the possible usefulness of IC351 as a treatment of several blood vessel…
- Trial name
- NCT00707187
- Testing
- Cialis
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Scleroderma, Systemic Sclerosis
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand…
- Conditions
- Scleroderma, Systemic Sclerosis, Raynaud Phenomena, Raynaud's Disease
- Trial name
- STAR (NCT02396238)
- Testing
- Celution Device
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- Cytori Therapeutics
Anticoagulation
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
The purpose of this study is to evaluate the APIXABAN use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation in Real-Life Setting in France, data from SNIIRAM (French data base).
- Trial name
- NCT02640222
- Testing
- VKA, Apixaban, dabigatran
- Where
- France
- Volunteers
- 321,501 people
- Sponsor
- Bristol-Myers Squibb
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with…
- Trial name
- NCT04040322
- Testing
- Iloprost Injection, for intravenous use
- Where
- 30 sites in United States
- Volunteers
- 198 people
- Sponsor
- Civi Biopharma, Inc.
Septic Shock
Activated Protein C and Corticosteroids for Human Septic Shock
This study aims at comparing the efficacy and safety of recombinant human activated protein C to that of low dose of corticosteroids and at investigating the interaction between these drugs in the management of septic shock
- Trial name
- APROCCHS (NCT00625209)
- Testing
- recombinant human activated protein C and hydrocortisone and fludrocortisone
- Where
- 4 sites in France
- Volunteers
- 1,241 people
- Sponsor
- University of Versailles
Acute Coronary Syndrome, Myocardial Infarction
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter
- Trial name
- WOEST-3 (NCT04436978)
- Testing
- 30-day DAPT, Guideline-directed therapy
- Where
- 20 sites in Belgium, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- St. Antonius Hospital
Pulmonary Embolism
Thrombolytic and Interventional Treatment of Pulmonary Embolism
Pulmonary embolism (PE) is a pulmonary vascular disease that seriously endangers human health. It has the characteristics of high morbidity, high mortality, high misdiagnosis rate and low detection rate.
- Trial name
- NCT03886194
- Testing
- interventional treatment in pulmonary
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Granulomatosis With Polyangiitis, Atherosclerosis
Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis
Granulomatosis with polyangiitis (GPA) is one of antineutrophil cytoplasmic autoantibody (ANCA) - associated vasculitis. Inflammation-induced thrombosis is considered to be a feature of systemic autoimmune diseases.
- Conditions
- Granulomatosis With Polyangiitis, Atherosclerosis, Thrombosis
- Trial name
- NCT03782870
- Testing
- echocardiography, lab tests
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Sepsis Syndrome, MODS
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Continuous renal replacement therapy is widely used in intensive care medicine, which is known as an alternative therapy to save injured kidney . Anticoagulation is an important part of this therapy.
- Conditions
- Sepsis Syndrome, MODS, AKI, Hemorrhage
- Trial name
- NMFADCICIP (NCT05382078)
- Where
- China
- Volunteers
- 188 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University